Skip Navigation

Cardiovascular Research 1998 39(1):194-215; doi:10.1016/S0008-6363(98)00083-2
© 1998 by European Society of Cardiology
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Curtis, M. J
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Curtis, M. J
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 1998, European Society of Cardiology

Characterisation, utilisation and clinical relevance of isolated perfused heart models of ischaemia-induced ventricular fibrillation

Michael J Curtis*

Cardiovascular Research Laboratories, Vascular Biology Research Centre, Cardiovascular IRG, and Pharmacology Group, King's College, Manresa Road, London SW3 6LX, UK

* Tel.: 171 333 4736; Fax: 171 376 8150; E-mail noVFib@kcl.ac.uk

The isolated perfused heart has been used increasingly during the last decade as a model for identifying actions of drugs on ventricular fibrillation (VF) induced by myocardial ischaemia. In addition, it has been used to explore the mechanisms responsible for the initiation and maintenance of VF, the concept of endogenous myocardial protection and the phenomenon of preconditioning. This article is a review of the available data (effects of drugs, sources of variation, comparison with other models and man, etc.) and an attempt to evaluate the possible clinical relevance. For several reasons, it is not possible to make a precise judgement on the absolute value of the model in terms of its ability to accurately predict the effectiveness of drugs in the prevention of sudden cardiac death, the main reason being the lack of a positive control, i.e. a drug with proven effectiveness against sudden cardiac death caused by VF in man. Nevertheless, the means by which one may reliably and reproducibly generate ischaemia-induced VF in different isolated heart preparations, and the factors (such as species, heart rate, perfusion constituents and involved zone size) that determine the incidence of VF are now well documented. Careful selection of species and experimental conditions permits the isolated heart of smaller inexpensive animals to function as a first line model for detecting anti-VF activity of probable relevance to phase 1 arrhythmogenesis (i.e., arrhythmogenesis during the first 30 min of ischaemia). In view of the absence of a clinical template from which to evaluate how well it predicts drug effectiveness in man, this model's clinical relevance, like that of all other preparations and models, can yet be neither accepted nor dismissed. Recent publication patterns suggest an increasing use of the model. Therefore, recommendations are made to facilitate its effective use.

KEYWORDS Antifibrillatory drugs; Arrhythmia models; Global ischaemia; Ischaemia; Langendorff preparation; Sudden cardiac death; Ventricular fibrillation; Working heart preparation


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Cardiovasc ResHome page
C. L. Stables and M. J. Curtis
Development and characterization of a mouse in vitro model of ischaemia-induced ventricular fibrillation
Cardiovasc Res, July 15, 2009; 83(2): 397 - 404.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
H. Clements-Jewery, D. J. Hearse, and M. J. Curtis
Neutrophil ablation with anti-serum does not protect against phase 2 ventricular arrhythmias in anaesthetised rats with myocardial infarction
Cardiovasc Res, March 1, 2007; 73(4): 761 - 769.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
R. Coronel, F. J.G. Wilms-Schopman, H. M. Den Ruijter, C. N. Belterman, C. A. Schumacher, T. Opthof, R. Hovenier, A. G. Lemmens, A. H.M. Terpstra, M. B. Katan, et al.
Dietary n-3 fatty acids promote arrhythmias during acute regional myocardial ischemia in isolated pig hearts
Cardiovasc Res, January 15, 2007; 73(2): 386 - 394.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
J. R de Groot and R. Coronel
Acute ischemia-induced gap junctional uncoupling and arrhythmogenesis
Cardiovasc Res, May 1, 2004; 62(2): 323 - 334.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
D. J. Mancuso, D. R. Abendschein, C. M. Jenkins, X. Han, J. E. Saffitz, R. B. Schuessler, and R. W. Gross
Cardiac Ischemia Activates Calcium-independent Phospholipase A2{beta}, Precipitating Ventricular Tachyarrhythmias in Transgenic Mice: RESCUE OF THE LETHAL ELECTROPHYSIOLOGIC PHENOTYPE BY MECHANISM-BASED INHIBITION
J. Biol. Chem., June 13, 2003; 278(25): 22231 - 22236.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
J. R. de Groot
A little gap junctional uncoupling too much
Cardiovasc Res, December 1, 2002; 56(3): 350 - 352.
[Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
R. Coronel, F. J. G. Wilms-Schopman, and J. R. deGroot
Origin of ischemia-induced phase 1b ventricular arrhythmias in pig hearts
J. Am. Coll. Cardiol., January 2, 2002; 39(1): 166 - 176.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.